Develops genetic medicines for rare neurological diseases.
Dec 2025Revenue $0.00/yrExpenses $103M/yr
No trendCash runway ≈ 2.6 years from Jun 2026
Figures by year
When will Neurogene be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $0.00 and expenses $103M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $0.00 | $103M | −$103M |
| Dec 2024 | $925K | $83.5M | −$82.6M |
| Dec 2023 | $0.00 | $55.6M | −$55.6M |
| Dec 2018 | $25.0M | $57.6M | −$32.6M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.